Can Azathioprine Cause Splenomegaly and Lymphadenopathy?
Yes, azathioprine can cause both splenomegaly and lymphadenopathy, though through different mechanisms and with varying clinical significance.
Splenomegaly
Azathioprine-induced splenomegaly is a well-documented adverse effect, primarily occurring through the development of nodular regenerative hyperplasia (NRH) of the liver leading to non-cirrhotic portal hypertension. This is a serious complication that requires immediate recognition and drug discontinuation.
Clinical Presentation and Mechanism
- Portal hypertension pathway: Azathioprine causes NRH, which leads to portal hypertension manifesting as splenomegaly, thrombocytopenia, and esophageal varices 1, 2
- Timing: Can develop after years of therapy (reported cases at 5 years and beyond) 1
- Key finding: Liver function tests may remain completely normal in two-thirds of cases, making this particularly insidious 2
- Associated findings: Thrombocytopenia, esophageal varices, and portal hypertension without cirrhosis 1, 2
Critical Monitoring Points
Monitor for the triad of:
- Thrombocytopenia (often the first sign)
- Splenomegaly on physical exam or imaging
- Normal or near-normal liver enzymes (do not be falsely reassured)
If portal hypertension is suspected, permanently discontinue azathioprine 2.
Lymphadenopathy
Lymphadenopathy associated with azathioprine occurs through two distinct mechanisms:
1. Lymphoproliferative Disease/Lymphoma
The FDA label explicitly warns that azathioprine increases lymphoma risk, particularly EBV-associated lymphomas 3. The British Association of Dermatologists guidelines note that 11 of 12 patients who developed Epstein-Barr-positive lymphoma had used thiopurines 4.
- Incidence: 0.5% in renal transplant recipients; lower but present in other populations 3
- Presentation: Lymphadenopathy with hepatosplenomegaly, fever, and systemic symptoms 5
- Risk increases with: Duration of therapy and degree of immunosuppression
2. Azathioprine Hypersensitivity Syndrome
A recently recognized manifestation: Hilar and mediastinal lymphadenopathy can occur as part of azathioprine hypersensitivity syndrome, typically within the first 3-4 weeks of therapy 6.
- Timing: Early (within first 4 weeks) 6, 7
- Associated symptoms: Fever, abdominal pain, nausea/vomiting, elevated CRP, leukocytosis 6, 7
- Key feature: Dose-independent, idiosyncratic reaction 6
- Eosinophilia: Usually absent (helps distinguish from other drug reactions) 6
Clinical Algorithm for Evaluation
When encountering splenomegaly or lymphadenopathy in azathioprine-treated patients:
Immediate assessment:
- Complete blood count (look for thrombocytopenia, pancytopenia)
- Liver function tests (remember: may be normal in NRH)
- Duration of azathioprine therapy
If splenomegaly with thrombocytopenia:
- Evaluate for portal hypertension (ultrasound with Doppler, FibroScan)
- Consider upper endoscopy for varices
- Liver biopsy may be needed to confirm NRH
- Discontinue azathioprine immediately
If lymphadenopathy:
- Early therapy (<4 weeks): Consider hypersensitivity syndrome—check CRP, fever curve, GI symptoms; discontinue drug
- Chronic therapy: Evaluate for lymphoproliferative disease—CT imaging, EBV serology, consider biopsy
- Assess for systemic B symptoms (fever, night sweats, weight loss)
Important Caveats
- The absolute risk of lymphoma remains low but increases with treatment duration 4
- Portal hypertension from NRH is irreversible even after drug discontinuation in many cases 2
- Hypersensitivity syndrome with lymphadenopathy is a newly described entity and may be underrecognized 6
- Do not assume normal liver enzymes exclude serious hepatic complications 2
The recommendation is to maintain high clinical suspicion for these complications, perform regular monitoring including CBC and physical examination for splenomegaly, and permanently discontinue azathioprine if portal hypertension or lymphoproliferative disease develops.